Back

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells

Grzywa, T.; Mehta, N.; Cossette, B.; Romanov, A.; Paruzzo, L.; Ramasubramanian, R.; Cozzone, A.; Morgan, D.; Sukaj, I.; Bergaggio, E.; Tannir, R.; Kadauke, S.; Myers, R.; Yousefpour, P.; Ghilardi, G.; Schuster, S.; Neeser, A.; Frey, N.; Goncalves, B.; Zhang, L.; Abraham, W.; Suh, H.; Ruella, M.; Grupp, S.; Chiarle, R.; Wittrup, K. D.; Ma, L.; Irvine, D. J.

2024-10-01 bioengineering
10.1101/2024.04.16.589780 bioRxiv
Show abstract

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B-cell malignancies, but many patients relapse due to failed expansion and/or progressive loss of CAR-T cells. We recently reported a strategy to potently restimulate CAR-T cells in vivo, enhancing their functionality by administration of a vaccine-like stimulus comprised of surrogate peptide ligands for a CAR linked to a lymph node-targeting amphiphilic PEG-lipid (termed CAR-T-vax). Here, we demonstrate a general strategy to generate and optimize peptide mimotopes enabling CAR-T-vax generation for any CAR. Using the clinical CD19 CAR (FMC63) as a test case, we employed yeast surface display to identify peptide binders to soluble IgG versions of FMC63, which were subsequently affinity matured by directed evolution. CAR-T vaccines using these optimized mimotopes triggered marked expansion and memory development of CD19 CAR-T cells in both syngeneic and humanized mouse models of B-ALL/Lymphoma, and enhanced control of disease progression. This approach thus enables vaccine boosting to be applied to any clinically relevant CAR-T cell product.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 6%
22.2%
Similar papers in this journal
2
Nature
○ 645 papers in training set
Top 1%
12.4%
Similar papers in this journal
3
Nature Biomedical Engineering
○ 47 papers in training set
Top 0.1%
6.7%
Similar papers in this journal
4
Science Advances
● 1243 papers in training set
Top 4%
5.5%
Similar papers in this journal
5
Science
● 477 papers in training set
Top 1%
5.4%
Similar papers in this journal
50% of probability mass above
6
Nature Chemical Biology
○ 119 papers in training set
Top 0.5%
4.8%
7
Nature Biotechnology
○ 172 papers in training set
Top 1%
4.0%
8
Nature Methods
○ 385 papers in training set
Top 3%
3.1%
9
Nature Nanotechnology
○ 32 papers in training set
Top 0.3%
2.4%
10
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 22%
2.4%
11
Cell
○ 431 papers in training set
Top 5%
2.0%
12
Nature Metabolism
○ 69 papers in training set
Top 1.0%
1.9%
13
Cell Research
○ 51 papers in training set
Top 0.5%
1.9%
14
Neuron
○ 337 papers in training set
Top 4%
1.5%
15
Nature Neuroscience
○ 252 papers in training set
Top 4%
1.4%
16
Cell Reports
○ 1498 papers in training set
Top 22%
1.3%
17
eLife
● 5828 papers in training set
Top 56%
1.3%
18
Nature Genetics
○ 286 papers in training set
Top 4%
1.1%
19
Nature Medicine
○ 125 papers in training set
Top 3%
1.1%
20
Blood
● 74 papers in training set
Top 1.0%
1.1%
21
Advanced Science
○ 286 papers in training set
Top 7%
1.1%
22
Nature Cell Biology
○ 118 papers in training set
Top 3%
1.1%
23
Nature Chemistry
○ 42 papers in training set
Top 0.8%
1.1%
24
Science Translational Medicine
● 127 papers in training set
Top 3%
1.0%
25
ACS Nano
● 113 papers in training set
Top 2%
0.8%
26
ACS Central Science
● 71 papers in training set
Top 2%
0.8%
27
Cell Chemical Biology
○ 94 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.